A case of primary ocular and central nervous system malignant lymphomawas reported which was first manifested as bilateral uveitis ten months before the neurological symptoms appeared. The lesion of lymphomain the central nervous system was clearly demonstrated as a heavy accumulation of N-isopropyl-123I-p-iodoamphetamine by single photon emission computed tomography. Since most brain tumors reportedly show a low uptake of N-isopropyl-123I-piodoamphetamine, single photon emission computed tomography with N-isopropyl-123I-piodoamphetamine could be helpful in making the diagnosis, as well as in visualizing primary central nervous system malignant lymphoma. (Internal Medicine 33: 92-96, 1994) 
Introduction
Uveitis is known to precede the symptoms of primary central nervous system (CNS) malignant lymphoma. Since most of these ocular lesions have been reported to represent infiltrations of malignant lymphoma, these cases have been termed "masquerade syndrome" and classified as primary ocular and CNS malignant lymphoma which are assumedto have multifocal neoplastic origin (1) (2) (3) (4) (5) (6) (7) (8) . In such cases, it is difficult to make a diagnosis of malignant lymphomauntil the CNSsymptoms appear.
Here we describe a case of primary ocular and central nervous system malignant lymphomain which bilateral uveitis appeared ten months before the CNSsymptomsemerged. In this case, single photon emission computed tomography (SPECT) with N-isopropyl-1 23I-p-iodoamphetamine ( 1 23I-IMP) clearly demonstrated a dense accumulation of 123I-IMP in the CNSlesion of malignant lymphoma. Most brain tumors are reported to show a low uptake of 123I-IMP (9), so SPECTwith 123I-IMP could be helpful in making the diagnosis of primary CNSmalignant lymphoma.
Case Report
A 37-year-old womannoticedblurred vision in August 1990 and was diagnosed as having idiopathic bilateral uveitis. As her visual acuity was gradually worsening, oral corticosteroid therapy was started in March 1991. Her visual symptoms rapidly improved. In June 1991, when steroid therapy was tapered off, she developed headaches, unsteadiness of gait and blurred vision, and was therefore admitted to our hospital. She was afebrile. Ophthalmological examination on admission disclosed bilateral decrease in visual acuity due to posterior uveitis. Neurological examination showed horizontal gaze nystagmus, slight dysmetria in her left arm and gait ataxia. There were no disturbances of higher function nor meningeal signs observed. Examination of cerebrospinal fluid (CSF) indicated slight pleocytosis (10 mononuclear cells and 6 atypical cells per jLil), a normal protein level (41 mg/dl) and an increased level of 62-microglobulin (4,571 Jig/1). Magnetic resonance imaging (MRI) performed immediately after admission revealed several intracranial lesions. Oneof them was located in the splenium, which showed low intensity on a Tl-weighted image (Fig. 1A ) and irregular intensity surrounded by high intensity on a T2-weighted image ( Fig. IB ) and proton image (Fig. 1C) . The splenium lesion was markedly enhanced by gadolinium (Gd)-DTPA and was clearly differentiated from the surrounding brain tissue ( Fig. 2A) . In addition, a T2-weighted image showed multiple high intense lesions located mainly in the left middle cerebellar peduncle (Fig. ID) . The splenium lesion was also enhancedon the contrast-enhanced computed tomographic scan (CT scan) (data not shown). Furthermore, we performed 123I-IMP SPECT at 15 minutes and 3 hours after intravenous administration of 123I-IMP (222 MBq) with HEADTOMESET-050 (Shimadzu Co., Kyoto). The first image obtained 1 5 minutes after administration showedunusually heavy accumulation of IMP in the splenium (Fig. 2B) , and this became more clear 3 hours after administration of IMP ( hyperchromatic nuclei consistent with large-cell lymphoma were found (Fig. 3) . Other laboratory findings were normal. Gallium scintigraphy showed increased uptake in both eyes and splenium.
However, bone-marrow biopsy, abdominal ultrasonography, thoracic and abdominal CT scans did not reveal any systemic lesions. From these findings, we diagnosed this case as primary ocular and central nervous system malignant lymphomafirst manifested as uveitis. She was initially treated with radiotherapy (RT) to both eyes (30 Gy) and intrathecal administration of corticosteroid and methotrexate (MTX). A combination regimen using pre-RT systemic MTXand intra-Ommaya MTX,whole-brain RT and post-RT high-dose cytosine arabinoside (Ara-C) was planned to follow (10). After she received systemic MTX(total 3 g) and intrathecal MTX(total 96 mg), we performed MRI and 123I-IMP SPECT again. On a Gd-DTPA enhanced Tl-weighted image, the splenium lesion was no longer enhanced by Gd-DTPA (Fig. 2D ). In addition, accumulation of IMP in the splenium markedly decreased both in the early image (Fig. 2E ) and delayed image (Fig. 2F) .
Since she developed pneumonitis after MTXtreatment, we exchanged the former protocol for a combination regimen using chemotherapy (dexamethasone, cisplatin and Ara-C) and wholebrain RT. The treatment was successful. She was discharged in November 1991. 
Discussion
Several reports describe that primary CNS malignant lymphomacould involve ocular tissues and simulate uveitis (1) (2) (3) (4) (5) (6) (7) (8) . Becauseocular symptoms are reported to often precede CNS symptoms in such cases, diagnosis of malignant lymphoma seemed difficult before CNSsymptoms appeared. Although cytologic examinationof vitreous aspirate wasreported to be useful for the diagnosis of malignant lymphomain the opthalmological field (3, 9) , it is good to always consider that uveitis can be an early manifestation of primary ocular and CNS malignant lymphoma, and to carefully follow-up the neurological examination of these patients. For the diagnosis of primary CNS malignant lymphoma, an increased B2-microglobulin level in CSF (ll) and neuroradiological findings on CT (12, 13) or MRI (14) have been reported to be useful. Actually, the increased level of B2-microglobulin in CSF and marked enhancement by contrast enhanced material on CT scans and by Gd-DTPAon MRscans were observed in the present case. In addition to these findings, a heavy accumulation of 123I-IMP was recognized both on the early and delayed images by SPECT. Since intravenously administered 123I-IMP passes through the blood-brain barrier and remains in the brain tissue for several hours, the distribution of 123I-IMP imaged by SPECT reflects the static image of the cerebral blood circulation ( 15) . 
